TORONTO--(BUSINESS WIRE)--Kyto Biopharma Inc. (“Kyto”), (OTCBB: KBPH), is pleased to announce that it has signed a licensing agreement with the Research Foundation of the State University of New York, (“RFSUNY”). The licensing agreement grants Kyto patent rights to the Transcobalamin (Vitamin B12) Receptor and to an additional broad group of other patents which are critical to Kyto’s research and development strategy for the treatment of cancer.
